A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease
This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's dise...
© 2019 Elsevier LtdAlzheimer's disease (AD) is the most common age-associated dementia. Many st...
Because of the changes in demographic structure, the prevalence of Alzheimer's disease is expected t...
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 s...
A molecular test for Alzheimer\u27s disease could lead to better treatment and therapies. We found 1...
A blood-based assessment of preclinical disease would have huge potential in the enrichment of parti...
A blood-based assessment of preclinical disease would have huge potential in the enrichment of parti...
Objective: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design: Baseli...
Objective: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design: Baseli...
BackgroundRecent Alzheimer's disease (AD) research has focused on finding biomarkers to identify dis...
<p><b>Objectives</b>: Alzheimer’s disease (AD) is the most common cause of dementia in elderly perso...
Background: Recent Alzheimer's disease (AD) research has focused on finding biomarkers to identify d...
BACKGROUND: The study aimed to validate previously discovered plasma biomarkers associated with AD, ...
The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment o...
Alzheimer's disease (AD) is a progressive brain disease with a huge cost to human lives. The impact ...
This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's dise...
© 2019 Elsevier LtdAlzheimer's disease (AD) is the most common age-associated dementia. Many st...
Because of the changes in demographic structure, the prevalence of Alzheimer's disease is expected t...
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 s...
A molecular test for Alzheimer\u27s disease could lead to better treatment and therapies. We found 1...
A blood-based assessment of preclinical disease would have huge potential in the enrichment of parti...
A blood-based assessment of preclinical disease would have huge potential in the enrichment of parti...
Objective: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design: Baseli...
Objective: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Design: Baseli...
BackgroundRecent Alzheimer's disease (AD) research has focused on finding biomarkers to identify dis...
<p><b>Objectives</b>: Alzheimer’s disease (AD) is the most common cause of dementia in elderly perso...
Background: Recent Alzheimer's disease (AD) research has focused on finding biomarkers to identify d...
BACKGROUND: The study aimed to validate previously discovered plasma biomarkers associated with AD, ...
The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and treatment o...
Alzheimer's disease (AD) is a progressive brain disease with a huge cost to human lives. The impact ...
This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's dise...
© 2019 Elsevier LtdAlzheimer's disease (AD) is the most common age-associated dementia. Many st...
Because of the changes in demographic structure, the prevalence of Alzheimer's disease is expected t...